Good day, and welcome to the First Quarter Fiscal Year 2023 Cardinal Health Earnings Conference Call. Today's call is being recorded. I will now hand the call over to Jason Hollar, Chief Executive Officer; and Trish English, Interim Chief Financial Officer. During the call, we will be making forward-looking statements. The matters addressed in the statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a full description of these risks and uncertainties. Please note that during the discussion today, our comments will be on a non-GAAP basis, unless they are specifically called out as GAAP. GAAP to non-GAAP reconciliations for all relevant periods can be found in the schedules attached to our press release. During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so that we can try and give everyone in the queue an opportunity. With that, I'll now turn the call over to Jason.

Thanks, Kevin, and good morning, everyone. Now that I've had a couple of months to settle into the CEO role, I'm feeling even more energized and excited about the opportunities in front of us. My recent conversations with customers, suppliers, employees, and shareholders have reinforced my perceptions that our company's role in healthcare and our mission to improve the lives of people every day remain as critical as ever. Our customers and their patients rely on us to deliver the right products to the right places at the right time. And yet, there's also a collective recognition of the need for simplification, focused execution, and clarification of our company's strategic direction. Our goal today, along with reviewing our recent results, is to summarize the key near-term priorities and our progress to date on our plans, which I will discuss later in my remarks. However, before I turn it over to Trish, let me share some initial perspective on the first quarter. Overall, our performance in the first quarter demonstrated continued stable fundamentals in our largest business and tangible progress in Medical. In Pharma, we tracked slightly ahead of our expectations, as we delivered growth while managing industry-wide inflationary headwinds. We are encouraged by the ongoing stability in prescription volumes and the strong performance of our generics program. In Medical, the quarter's results were also a little better than the expectations we announced in September. While I'm pleased with our team's efforts in the quarter to achieve these results, there is more work to be done to drive better, more predictable financial performance in line with the underlying potential of this business. We are highly focused on executing our Medical Improvement Plan initiatives, which I'll cover in greater detail later in my remarks. Across the company, our team is operating with urgency to drive our businesses forward and is committed to creating value for our shareholders. Now, I'll turn it over to Trish to dive deeper into our results and outlook.

Thanks, Jason, and good morning, everyone. It's great to speak with you all. Today, I'll share details on three areas of focus. Our consolidated first quarter results, the key drivers underlying our segment's performance, and our updated fiscal 2023 outlook before turning it back to Jason for final remarks. First quarter total company revenue increased 13%, driven by Pharma segment sales growth. Gross margin decreased 2% to $1.6 billion, due to net inflationary impact in medical and one month impact of the Cordis divestiture, partially offset by our Pharma Generics program performance. Consolidated SG&A increased 7%, reflecting inflationary supply chain costs and other operating expenses such as higher costs to support Pharma sales growth. This increase was partially offset by the Cordis divestiture and benefits from enterprise-wide cost savings initiatives. Operating earnings decreased 20% to $423 million, reflecting the decline in Medical segment profit, primarily due to net inflationary impact, and partially offset by growth in Pharma segment profit. Now moving below the line. Interest and Other decreased 25% to $27 million, primarily driven by increased interest income from cash and equivalents. As a reminder, our debt is largely fixed rate, resulting in a net benefit from rising interest rates. Our first quarter effective tax rate finished at 16.9%, approximately 7 percentage points lower than the prior year due to certain favorable discrete items. Diluted weighted average shares were $273 million, 6% lower than a year ago due to share repurchases. We are focused on balanced, disciplined, and shareholder-friendly capital deployment, and in mid-September, we initiated a $1 billion accelerated share repurchase program that we expect to complete in the second quarter. The net result for the quarter was earnings per share of $1.20. Now, turning to the balance sheet. We generated first quarter operating cash flow of approximately $25 million. This includes total litigation payments of approximately $390 million, primarily consisting of the second payment under the national opioid settlement. Adjusted free cash flow in our first quarter was $342 million. We ended the period with a cash position of $3.5 billion, with no outstanding borrowings on our credit facility. Now turning to the segments, beginning with Pharma. First quarter revenue increased 15% to $46 billion, driven by branded pharmaceutical sales growth from existing and net new Pharmaceutical Distribution and Specialty customers. Pharma segment profit increased 6% to $431 million, driven by Generic program performance and a higher contribution from Brand and Specialty products, partially offset by inflationary supply chain costs. We were pleased to see strong execution and continued consistent market dynamics in our generic program, including Red Oak. As we previously noted, inflation continues to impact supply chain costs across the industry, particularly within transportation and labor. We saw an approximate $20 million year-over-year headwind from these areas, which was consistent with our expectations. This headwind was effectively offset by year-over-year tailwind from our completed ERP technology enhancements and lower opioid-related legal costs. Okay. Turning to Medical. First quarter revenue decreased 9% to $3.8 billion, driven by lower products and distribution sales, primarily due to PPE pricing and volumes, and to a lesser extent, the Cordis divestiture. Continued strong growth in our at-Home Solutions business offset some of this revenue decline. Medical segment loss of $8 million was due to net inflationary impact in products and distribution, as well as a lower contribution from PPE, both of which I will discuss in more detail. Importantly, these results reflect approximately $20 million in total inventory charges related to our previously announced simplification actions. This includes the sale of our gloves portfolio that is primarily utilized in non-health care industries. As a reminder, this non-core product line has been a source of volatility and distraction in recent years. These actions, despite the one-time costs, are an example of our ongoing commitment to strengthening the medical product and distribution business through simplification. During the quarter, the growth impacts from incremental inflation in our product and distribution business were in line with our expectations of approximately $150 million, and we successfully achieved our inflation mitigation target of 25%. Our mitigation efforts have continued to accelerate, most notably with the implementation of the second wave of product pricing actions in July. Jason will elaborate on our plans for further mitigation shortly. Now, a quick update on the overall utilization environment. We've previously noted some overall volume softness in our products and distribution business, including a lower demand for PPE, which we believe primarily reflects customers' higher inventory levels. In the first quarter, we saw generally consistent overall products and distribution volumes sequentially, including with PPE. While we do anticipate gradual improvement in volumes relative to these recent lows, we continue to expect choppiness in demand levels going forward. Now for our fiscal 2023 outlook, beginning with slide eight. We are reiterating our EPS guidance of $5.05 to $5.40. This includes our updated medical segment outlook, which has been adjusted for the impact of simplification actions in the first quarter and a few below-the-line improvements. Based on the first quarter performance, we are confident in lowering the top end of the guidance for interest and other, our effective tax rate, and diluted weighted average shares for the fiscal year. We now expect interest and other in the range of $140 million to $160 million, an effective tax rate between 23% and 24%, and diluted shares between $262 million to $264 million. Our expectations for the remaining items remain unchanged. We are also reiterating our fiscal 2023 outlook for the Pharma segment. We continue to expect revenue growth in the range of 10% to 14% and segment profit growth in the range of 2% to 5%. Before transitioning to medical, two key call-outs on the Pharma cadence. First, with a stronger start to the year, we now expect more balanced year-over-year profit growth between the first and second half of fiscal 2023. Specifically, for the second quarter, we expect segment profit dollars to be similar to the first quarter. Now turning to Medical. We expect segment profit ranging from flat to a decline of 20%, which, as I indicated, reflects the impact of the simplification actions in the first quarter. With respect to inflation and our mitigation actions, there is no change to our expectation of a net impact of approximately $300 million in fiscal 2023 or a minimal year-over-year impact. The macroeconomic environment remains dynamic. While we've seen some decreases in spot rates of certain cost drivers, such as international freight, other areas such as commodity costs remain significantly elevated. These product costs are capitalized into inventory. In the current environment of elongated supply chain reflected in our P&L results on an approximate two-quarter delay. While we now expect growth inflation in the second quarter to be similar to what was seen in Q1, we are implementing additional actions and working proactively to mitigate these pressures. It's important to note that we continue to expect that as we exit the year, the run rate of our mitigation actions will offset at least 50% of the growth impact from inflation. On Medical's quarterly cadence, in Q2, we expect similar segment profit dollars compared to the first quarter, excluding the impact of the first quarter simplification actions. We continue to expect a substantial majority of segment profit to come in the second half of fiscal 2023, particularly in the fourth quarter. This sequencing primarily reflects our assumptions around inflation, inflation mitigation, and PPE. With that, I'll now turn it over to Jason.

Thanks, Trish. I concluded our August earnings call with three key takeaways that I’d like to provide updates on. Number one, improving the underlying performance of the Medical segment through our Medical Improvement Plan initiatives. The key driver to achieving our segment profit target of at least $650 million by fiscal 2025 is our mitigation actions for inflation and global supply chain constraints. Though elevated inflation has persisted in the macro environment for longer than expected, we are on track to exit fiscal 2023 offsetting at least 50% of the gross impact on our business. As I previously mentioned, we plan to fully address the impact of inflation and global supply chain constraints through mitigation initiatives by the time we exit fiscal 2024. Our third wave of price increases went into effect on October 1, and we are planning additional actions for the third quarter. To date, we have adjusted product categories representing nearly 90% of US Cardinal Health brand sales, excluding PPE. Additionally, we successfully adjusted language in product contracts as they've renewed to allow for greater pricing flexibility to respond to macroeconomic dynamics. We’ve also executed distribution fee increases to offset higher transportation, labor, and fuel costs and continue to explore other opportunities for further offsets with urgency. Outside of our mitigation actions, we expect the largest contributor to our growth to be our ability to optimize and grow our $4.6 billion Cardinal Health brand portfolio. This will be achieved through new product innovation and increased product availability as a result of targeted investments. Additionally, I'm confident in our ability to optimize our cost structure and our sourcing and manufacturing footprints as we focus on driving simplification across the medical organization. The team is energized by the goals we have laid out in the medical improvement plan and has already hit the ground running on execution. Moving to item number two, for the Pharma business, continuing to build upon the growth and the resiliency that we've seen by executing in the core and accelerating our growth areas, primarily Specialty. Similarly, continuing on talent and leadership, we are excited about the appointment of Debbie Weitzman to CEO of the Pharma segment. Debbie has a deep understanding of our industry landscape, long-standing and strong relationships with our customers, and a proven track record as a commercial and operations leader across her 17 years at Cardinal Health. Debbie's deployment was part of our recently announced segment restructuring designed to reduce complexity, drive productivity and efficiency gains, and simplify how our customers and our manufacturing partners do business with us. These changes are intended to maximize the strength of our pharmaceutical distribution and Specialty businesses, bringing together similar services under one team, enabling us to respond faster and more effectively to changes in the healthcare landscape while keeping the customer at the center of everything we do. Simply, it is allowing us to reposition with both the right talent and organizational design. In Specialty, we have a robust service offering, both downstream with providers and upstream with biopharma manufacturers, and we continue to build upon our capabilities. In the area of oncology, we've expanded our best-in-class offering for value-based care, the Navista TS, which will continue to serve as a vital resource for oncologists transitioning to the new CMS enhancing oncology model. In rheumatology, we've closed on our recent tuck-in acquisition of the Bendcare GPO and our investment in our managed services organization has expanded our capabilities in the space and contributed to new customer growth. In just 30 days, this cross-functional leadership team worked diligently to onboard over 250 healthcare providers onto our distribution and logistics platforms. With biosimilars, we remain well positioned to distribute and provide the surrounding services as they come to market, particularly in the new therapeutic areas and sites of care. We continue to expect increased contributions from biosimilars in fiscal 2023 and beyond. Upstream and Specialty, our third-party logistics business continues its strong growth with more than double the launches in the first quarter compared to a year ago, as well as double-digit new contract wins. Our continued investment towards the digital transformation of our Sonexus access and patient support business has enabled us to realize benefits from new business wins and expansion of existing clients. And finally, number three, we have a relentless focus on shareholder value creation. This includes maximizing sustainable, profitable growth and cash flow generation, as well as a return of capital to shareholders. We continue to expect strong and resilient cash flow generation, supporting our capital allocation priorities. We are prioritizing organic growth, deploying CapEx to the highest value projects. We've made tremendous progress in reducing our long-term debt, which has created additional flexibility for shareholder returns. We were pleased to initiate the $1 billion accelerated share repurchase program in the first quarter and continue to expect $1.5 billion to $2 billion in total share repurchases in fiscal 2023, in addition to our ongoing dividend of over $500 million annually. Beyond these actions, we also announced enhancements to our governance structure, including four new independent Board members and a new business review committee, tasked with supporting a comprehensive review of our company's strategy, portfolio, capital allocation framework, and operations. Our business review committee, which I chair, has already held multiple meetings and is working through the detailed review covering every business. We expect to share conclusions publicly at an Investor Day in the first half of calendar 2023. In closing, I recognize there is still a lot to accomplish, yet I remain excited about these opportunities to drive growth. I believe that our resilient business model, robust operating cash flow generation, favorable capital structure, and capital allocation flexibility differentiate us in this time of macroeconomic uncertainty, and I am confident in our future. Before we open up to Q&A, I do want to spend a moment thanking our dedicated team around the globe. We've had a number of opportunities to connect with them across the last couple of months, and it is truly a privilege to lead every day. They are driving the execution of the initiatives that we've discussed to date to deliver for our shareholders, for our customers, and for their patients, and we are very much looking forward to the opportunities that remain ahead. With that, we will take your questions.

Thank you. We will take the first question from Elizabeth Anderson with Evercore.

Hi, guys. Thanks so much for the question. I was just wondering if you could talk a little bit about the sort of embedded expertise in the back half of the year. You obviously had the first quarter, and you had some nice outperformance in hitting some early milestones and key initiatives. But in terms of how we think about that outperformance versus how you still see the progression in terms of the quarterly ramp in the back half, more color on that would be very helpful. Thanks.

Sure. And as for your question, Elizabeth, are you specific to any particular business, or are you just talking generally?

Specifically in terms of Medical, but I would also be curious about the Pharma side as well.

Okay. For Medical specifically, the biggest driver by far will be the mitigation actions to address inflation. Our first pricing actions went in place on March 1 of fiscal 2022. Then we had another wave in July at the very beginning of fiscal 2023, and another price adjustment that occurred on October 1. We do expect further price adjustments in the third quarter of the fiscal year. At the same time, we would expect, especially in the fourth quarter of fiscal 2023, to start seeing some of the lower costs, particularly with the international freight piece, finally starting to hit our P&L. As Trish highlighted in her comments, the supply chain remains very elongated, so we anticipate that it will take a couple of quarters before lower costs actually come through the P&L. As we indicated in our comments, international freight is really the only area of any significance where we are seeing cost reductions. We do see some of the other commodities coming down, but not to the same extent. The other key component from a first half, second half perspective for Medical is just the normalization of PPE. We talked about the higher-cost PPE being on our balance sheet when volumes fell quite a bit in the latter part of fiscal 2022, which meant that the higher costs stayed on our balance sheet longer. While we're pleased to see that it feels like we've come off the lows here from the fourth quarter in terms of demand, it remains something that will take a few quarters to work through. Beyond that, we expect just normal cost reductions and other growth initiatives over the course of the year to build up. Within Pharma, the specific item to remember from a first half, second half perspective is just the recognition of brand inflation. While that continues to be a small portion of our overall brand margin, less than 5%, it does remain highly concentrated in the third quarter. That’s the biggest driver for that particular business. Next question, please.

We will now take the next question from Lisa Gill with JPMorgan.

Alright. Thanks very much. Jason, I want to spend a couple of minutes on the pharmaceutical distribution side of your business. A few things. One of the things that really stuck out to me is you talked about strong performance in your generic program, and having enhancing programs going forward. I kind of think about where we need to be in generics. So maybe can you talk about what you're seeing in the market and incremental opportunities? And then secondly, when I look at the revenue on pharmaceutical distribution, you're coming in well above where the industry is. Can you maybe just talk about where you see that over time? And again, even your guidance is above where industry rates are. What's the key drivers there?

Yes. Let me start with the revenue point. The revenue for this particular quarter we highlighted was driven by brand products with our larger customers. When you think about the flow-through of that, that typically brings with it a lower margin profile, but brand has been very strong, and our larger customers have been an overweight of that. So we are kind of winning with the winners. Our larger customers have been growing nicely, which has been driving our revenue quite a bit higher, but tends to be the lower margin product. That's why you don't see quite the same flow-through in margin dollars. That's fairly consistent with what we've seen for quite some time. We also highlighted in the third quarter of fiscal 2022 some new business wins that did benefit our revenue. And with that, it means that for the first half of fiscal 2023, we would anticipate our revenue having a little bit of a tailwind relative to the full year, because we will then anniversary lap that new business win come the third quarter of fiscal 2023. As for your first question on generics — Yes. It continues to be a very consistent dynamic in the marketplace. Some of the new business wins have benefited that as well. We continue to have very strong performance within Red Oak Sourcing. The underlying utilization continues to be much more consistent and stable and predictable than what we've seen since the beginning of the pandemic. It feels a little bit more as business as usual, with less fluctuations, driving margin through sourcing, and driving the new business through our system. So those are the primary drivers.

Next question, please.

Great. Thanks for taking my question. I wanted to talk a little bit about the contracting. I think the last time Cardinal went through a lot of contracting during COVID, it ended up working against you as things reversed. So I just want to understand more about how you're amending these contracts. Are customers comfortable with this? Is there any pushback? There are seemingly efforts amongst almost all hospital companies to reduce their supply costs right now or reduce costs in general. So just wondering how it works? Is it impacting you immediately, or is this more of a cushion for longer term? Anything there would be helpful. And then one other follow-up. I read that there was a real estate transaction done, and now that was part of the business review. Potential outcomes were to monetize some real estate. Can you talk about the opportunity size to be able to do that in terms of generating capital for the business?

Sure. On the contracting, first of all, Kevin, I'm presuming you're talking about the medical inflationary price impacts?

Yeah.

Yeah, okay. The way the pricing that we've defined, those are temporary in nature to get us to the contracting that you're talking about. As the contracts renew, those temporary price increases are then flowed through to the permanent structure with adjustments within so that we don't encounter the same issue in the future that we've had to experience before. These contracts roll over the course of multiple years, and we're still in the earlier phases of an innings with that. However, I'll tell you, it's going consistent with my expectations. These are never easy conversations. But to your point, there is inflation everywhere. While some of this is more temporary in nature, a lot of it is going to be long-lasting and permanent. Think about specialty labor; those costs are never going to come down, and a lot of the transportation costs seem likely to remain at very elevated levels for quite some time. In regards to real estate transactions, we've had some small transactions. Nothing material at all to call out. There’s always evaluation. We do own some real estate. It is a component of one of those factors that we look at. At this point, it's too early to talk about any opportunity with that. Next question please.

The next question comes from Erin Wright with Morgan Stanley.

Great. Thanks. Can you speak a little bit to the long-term strategy and what's feasible in terms of your opportunity to improve mix and increase your exposure to Specialty over time? And as we think about specialty, can you also speak to the biosimilar opportunity and your near-term positioning to participate with Humira biosimilars as well as others? Thanks.

Yes. First and foremost, I appreciate and understand the question. This is a key reason for our recent reorganization within the Pharma segment. We have structured the team to have Specialty and Pharma Distribution together, reducing complexity, driving not just productivity but, more importantly, simplifying how we go to market with our customers and our manufacturing partners. This is all to recognize the importance of driving that favorable mix. The market is going to, in part, be a rising tide, but we definitely want to do as much as possible to participate in that growth. We just recently acquired Bendcare, which gives us additional exposure here. We have invested organically in all the different businesses and tools referenced in my script. We are investing both inorganically and organically and have now a structure and a leadership team that's intensely focused on this, so we feel very well positioned to take advantage of that future growth. On biosimilars, that is absolutely a component of this as well. We've invested in our capabilities and our team, and we participate in that today. It is a nice driver for our business, but not large enough that we've called it out specifically. Nonetheless, it is an area that we anticipate further opportunities for us, and it fits nicely into our capabilities. I know we get a lot of questions specifically about Humira and how that will benefit us. There's a lot to be played out here regarding how all participants drive their different processes, particularly the payers and PBMs, so a lot is to be learned there. But we are positioned well to take advantage of that. Next question please.

Next question please.

Good morning. I have one kind of just technical question and then a bit more on the numbers. So first on the ASR, you said you launched it in mid-September. Is there any way to quantify how much of the ASR you completed in 1Q relative to the timing of the 2Q finish? On the guidance, and I hear you on especially the trajectory of medical per Elizabeth's question earlier. But if you think about the moving pieces and what you updated today, it seems like there are more tailwinds when it comes to tax, interest expense, and share count than there are headwinds on the medical guide down. Any thought about why reiterating the guide versus not maybe bringing up the low end of the minimum?

Sure. As it relates to the ASR, your technical question — Yes, about 80% is what you would expect for the immediate benefit. As you appropriately referenced, it was implemented in mid-September, so a relatively small impact to the current quarter. Regarding guidance changes, well, hey, it's the first quarter. It’s certainly early. We're also talking about a fairly uncertain macroeconomic environment while we're looking at a lot of news and external references for utilization. So as our comments highlighted, we did not see a lot of surprises regarding utilization in either segment this particular quarter. That was certainly welcome, given what the last couple of years have looked like. But we continue to see more data points on that through various references, something we keep evaluating. Mathematically, I don't think there's that much difference in terms of the offsets we took, both in the takedown with medical driven, in part, by the simplification efforts as well as those other items where we took the top end down. It's still a reasonable range considering how early it is in the year and the drivers around us.

Next question please.

Thank you. I'd like to return to Medical and relative to the offset that you're attempting to achieve in 2023. It sounds like we have three factors: the pricing efforts, letting some of the supply chain and costs flow through or normalize, and then access to private label. Could you speak to what portion of the offset for fiscal year 2023 falls into those buckets, if you think those are the right buckets? And then as you move to 2024, how does that change in terms of how much is driven by each of those factors?

By far, it’s pricing. That is – there's the opportunity. What we want to do is work with our customers as much as possible to reduce what is necessary to flow through in terms of pricing, but the amount that can be moved on those items as well as others is relatively small. Pricing will be the predominant element there. The other component is just the cost coming down naturally as well. So we have two things happening between now and the end of the fiscal year. Pricing will continue to go up period-to-period, quarter-to-quarter. Our costs will peak at some point here, which we are pretty close to. We indicated similar gross costs in Q1 as what we expect in Q2, specifically regarding the international freight piece, that we have confidence in seeing down. However, the other components to inflation and other commodities are seeing some come down a little bit in some areas, not very significantly, and certainly at a pace less than what we had thought. A handful are actually going up. Overall, I expect to exit the year with a slightly lower cost run rate than what we're entering the year with. Next question.

Our next question comes from George Hill with Deutsche Bank.

Yeah. Good morning, guys, and thanks for taking the question. Jason, I'm going to come back to the MedSurg segment again. I was just wondering if there's a way to quantify like what part of the book has the new contracting terms in place? I don't know if you can talk about actions taken by peers. And then kind of – I kind of roll that into kind of the timing of implementation like you talked about the two-quarter lag between — not really the lag, but like the timing of the supply chain in that segment of the book. I'm just trying to think about how long it takes the entire book to get re-contracted into the new terms? What is the end date by which we should expect the full MedSurg book to kind of be operating under the new model?

It’s going to take at least a few more years to receive the full impact of the new contracting terms. It will be a consistent strategy between now and then. We have multiple product lines with different GPOs and customers, so it's a consistent stair-stepping process. You can think about it as every day, and it's incredibly important that we roll over these temporary prices into permanent prices given the permanence of many of these costs. We feel it's the right plan and right action, and we haven't been surprised with this at this stage. Next question, please.

Next question please.

Hi. Good morning. I might just ask, obviously, you've got a lot of things going on and seemingly having some success with your simplification and mitigation strategies. Now you have this business review committee. Are the guardrails as to the things you're already doing to improve performance versus what the business review committee is doing pretty clear? Did I hear you right in the prepared remarks that you think a review committee will have an update at the calendar 2023 Investor Day? I assume that would be preliminary if there's anything to share then.

Yes, there's a charter for the business review committee which is very consistent with what I provided. Of course, there's a portfolio element and a strategy operations element. The guardrails are as I described and it's clear what we work on. The committee acts similarly to other board committees, supporting insights and advice to the broader board while being collaborative. We expect to have an Investor Day in the first half of calendar 2023, where we plan to have an update as to what is possible to share at that time. Next question, please.

Our next question comes from Charles Rhyee with Cowen.

Yeah. Thanks for taking the questions. Just two really here. Just a follow-up on the Medical guide; I might have missed it, but — obviously, you've changed it. Has there been any change in your assumptions in the macro environment between July and now that's — is it really macro-driven? Because it seems like you have control over the pricing part of things. Is it just waiting for the environment itself and some of the natural inflation that's floating around here to come in line to get to your targets? And then secondly, there's been news about shortages in amoxicillin. Just your thoughts here on truck shortages, elsewhere possibly in the supply chain, any thoughts on the outlook there? Thanks.

In terms of Medical, the underlying performance we are anticipating for the business is relatively unchanged. The key item we highlighted is the simplification cost that's been wrapped into this. But the underlying business volume utilization and performance elements are relatively unchanged. There’s always puts and takes; not a lot of new news there for either business. As for product shortages, there’s always some in any business, but nothing unusual or significant that I anticipate being an impact for the segment this quarter or this fiscal year. Sourcing is crucial, especially for Generics, while Red Oak Sourcing is a huge driver for cost control and delivery. We have seen strong demand for some of those products like amoxicillin, but again, we don’t expect lasting impacts. Next question, please.

And our last question comes from Steven Valiquette with Barclays.

Great. Thanks. Good morning. So you touched on this topic a little bit, but this quarter, we saw your largest publicly traded hospital distribution and self-manufacturing MedSurg competitor really struggle with delayed product reorders by their acute care hospital customers who chose to deplete the stockpiled items. I know you have a different set of SKUs versus that competitor for the self-manufacturing component. Can you confirm that you generally are able to successfully track the level of inventory sitting within your health system customers in the Medical segment? Currently, we are hopefully not seeing a similar inventory destocking trend within the health system customer base that could be a risk factor for the recovery as the fiscal year progresses.

Yes, those types of comments are very consistent with what we've been saying in the last couple of quarters. We have seen destocking of our customers' inventory. We are close with them, and that dialogue is ongoing. We referenced in our comments that our volume, specifically related to PPE, but even more broadly, is fairly consistent sequentially from Q4 of last year to Q1 of this year. While it's still early in Q2, I can say that we haven't seen anything significantly different at the beginning of this quarter as well. However, there is nothing else to add at this point. I am pleased with the progress that we're making in our core business fundamentals, both segments are driving lasting improvements while maintaining a focus on shareholder value creation.

Thank you for joining today's call. You may now disconnect.